Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Registration statement is filed with the SEC for a secondary offering of 5 mil. shares of common stock. The La Jolla, California developer of human-based tissue products for therapeutic applications plans to use anticipated proceeds of approximately $16.6 mil. to fund operations including clinical trials and regulatory filings, investments in joint ventures and strategic alliances, R&D and general corporate purposes
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.